Adverum Biotechnologies/$ADVM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adverum Biotechnologies
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Ticker
$ADVM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
155
ISIN
US00773U2078
Website
ADVM Metrics
BasicAdvanced
$52M
-
-$7.22
1.02
-
Price and volume
Market cap
$52M
Beta
1.02
52-week high
$10.14
52-week low
$1.78
Average daily volume
258K
Financial strength
Current ratio
3.565
Quick ratio
3.311
Long term debt to equity
325.293
Total debt to equity
352.653
Profitability
EBITDA (TTM)
-154.842
Gross margin (TTM)
-8,937.80%
Net profit margin (TTM)
-15,079.90%
Operating margin (TTM)
-15,818.10%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-48.76%
Return on equity (TTM)
-144.51%
Valuation
Price to revenue (TTM)
52.033
Price to book
1.97
Price to tangible book (TTM)
1.97
Price to free cash flow (TTM)
-0.462
Free cash flow yield (TTM)
-216.22%
Free cash flow per share (TTM)
-538.39%
Growth
Earnings per share change (TTM)
-29.80%
10-year revenue growth (CAGR)
2.99%
3-year earnings per share growth (CAGR)
-22.95%
10-year earnings per share growth (CAGR)
-10.35%
What the Analysts think about ADVM
Analyst ratings (Buy, Hold, Sell) for Adverum Biotechnologies stock.
ADVM Financial Performance
Revenues and expenses
ADVM Earnings Performance
Company profitability
ADVM News
AllArticlesVideos
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
GlobeNewsWire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adverum Biotechnologies stock?
Adverum Biotechnologies (ADVM) has a market cap of $52M as of June 28, 2025.
What is the P/E ratio for Adverum Biotechnologies stock?
The price to earnings (P/E) ratio for Adverum Biotechnologies (ADVM) stock is 0 as of June 28, 2025.
Does Adverum Biotechnologies stock pay dividends?
No, Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Adverum Biotechnologies dividend payment date?
Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders.
What is the beta indicator for Adverum Biotechnologies?
Adverum Biotechnologies (ADVM) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.